Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer
Randomized Study of Docetaxel Versus Docetaxel Plus Genasense™ (G3139; Bcl-2 Antisense Oligonucleotide) in Patients With Previously Treated Non-Small Cell Lung Cancer
Sponsor: Genta Incorporated
Listed as NCT00030641, this PHASE2/PHASE3 trial focuses on Lung Cancer and remains ongoing. Sponsored by Genta Incorporated, it has been updated 6 times since 2001, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2/PHASE3
Status: Unknown Status → Unknown · Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2_PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE2_PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE2_PHASE3
First recorded
Oct 2001
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Genta Incorporated
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Arlington, United States, Atlanta, United States, Augusta, United States, Aurora, United States, Birmingham, United States, Charleston, United States, Chicago, United States, Concord, United States, Dallas, United States, Detroit, United States and 30 more location s